Published: [October 27, 2026]
StartupFeed Quick Take
- Two AI pharma deals abroad in October 2026 carried headline values of up to $1.5 Bn and $1.1 Bn.
- The cash paid up front in the bigger one was $40 Mn.
- India’s Technology Development Board signed Rs 86 crore for Bengaluru’s Peptris Technologies on October 12.
India’s government signed a Rs 86 crore cheque for Bengaluru’s Peptris Technologies on October 12, to push four AI-discovered molecules towards human trials.
Three days later, AstraZeneca signed an AI deal of its own. Its press release of October 15 puts the value at up to $1.5 Bn.
Eli Lilly followed on October 19 with a drug delivery deal worth up to $1.1 Bn. Two deals. One month.
Together they carry roughly $2.6 Bn in headline value. We added the two October deals ourselves.
AI Pharma Deals Crossed $2.6 Bn Abroad in October 2026
AstraZeneca is paying insitro $40 Mn now. The rest, up to $1.46 Bn, lands only if the work clears development and sales milestones.
The two will hunt drug targets in MASH, a severe liver disease, and in cardiomyopathies, which damage the heart muscle. AstraZeneca keeps exclusive worldwide rights.
insitro brings a platform it calls Virtual Human, which pairs lab-grown cell models with machine learning. AstraZeneca will run and fund the trials that follow.
Sharon Barr, who heads AstraZeneca’s biopharmaceuticals research, put the reason plainly:
“One of the most critical decisions in R&D is selecting the right target.”
Sharon Barr, executive vice president and head of BioPharmaceuticals R&D, AstraZeneca. From the company press release, October 15, 2026.
Eli Lilly’s agreement with METiS TechBio has the same shape. METiS gets a low double-digit million sum up front, then up to $1.1 Bn in milestones.
The Hong Kong-listed firm designs the fat bubbles that carry genetic medicines into cells. Its AiLNP system does that design work on a computer.
What India Signed in the Same Month
The Technology Development Board sits under the Department of Science and Technology. It signed the Peptris agreement on October 12, using the Research Development and Innovation Fund.
It is not a grant. The Rs 86 crore is optionally convertible debt, a loan the government can later turn into shares.
The VIGOR programme costs Rs 172 crore in total and runs for three years. All four candidates sit at technology readiness level four today, which means lab-proven, not people-proven.
The four are PEPR111 for neuromuscular disease and cancer, PEPRX101 for hair loss, PEPR202 for nerve pain, and PEPR112 for Duchenne muscular dystrophy.
Private money moved earlier in the year. Mankind Pharma tied up with Denovo Sciences on July 1 to run an AI drug discovery programme, with no value disclosed.
Public money is building up behind it. The Union Budget 2026-27 set aside Rs 10,000 crore over five years for biologics and biosimilars.
The Headline Numbers Are Mostly Milestones
Compare the cash, not the headline. AstraZeneca’s $1.5 Bn is $40 Mn now and $1.46 Bn later, if the science works.
Lilly has done this more than once. In April it agreed to pay Profluent up to $2.25 Bn for AI-designed enzymes, before royalties.
It also signed with Insilico Medicine this year, in a deal worth up to $2.75 Bn. None of these numbers is cash in hand.
Peptris faces the same test, in rupees. Its money is released against milestones, so the full Rs 86 crore arrives only if each stage is cleared.
| Deal | Signed | Headline value | Paid up front |
|---|---|---|---|
| AstraZeneca and insitro | October 15, 2026 | Up to $1.5 Bn | $40 Mn |
| Eli Lilly and METiS TechBio | October 19, 2026 | Up to $1.1 Bn | Low double-digit millions |
| Eli Lilly and Profluent | April 28, 2026 | Up to $2.25 Bn | Not disclosed |
| GSK and Relation Therapeutics | July 30, 2026 | Up to $110 Mn | Not disclosed |
| TDB and Peptris Technologies | October 12, 2026 | Rs 86 Cr | Released against milestones |
Read the right-hand column first. Every number there is small, and every number beside it is a promise.
The structure protects the buyer. A drugmaker pays little to start, then pays more only when a molecule survives.
Proof in a Lab Is What Buys the Deal
GSK shows what actually closes these deals. It widened its work with Chai Discovery in October, but only after its own scientists tested the AI designs.
Chai’s models produced designs for GSK targets without any extra training. GSK’s laboratory testing found binders to every target it tried.
Data is the other currency. GSK agreed in July to pay Relation Therapeutics up to $110 Mn, mostly to generate large human cell datasets.
That is the gap an Indian founder has to close. Not a deck. A lab result, and a dataset nobody else owns.
Peptris is further along than most. Its four molecules are already designed and waiting for the studies that come before human trials.
The judgement is simple. India has the molecules. What it lacks is a buyer willing to pay like AstraZeneca.
What this means for you: If you run an Indian AI drug discovery startup, the price of your platform is now set abroad. Get one lab-validated result and a dataset nobody else owns before you pitch a global drugmaker in 2027.
StartupFeed Insight
India’s cheque is not small because the science is weak. It is small because the buyer is a government, not a drugmaker. Abroad, a pharma company pays $40 Mn to start a target hunt and promises $1.46 Bn on the result. Peptris gets debt, and the risk stays with the founder. The fix is not a bigger government fund. It is an Indian drugmaker writing the first real cheque, the way Mankind Pharma started in July. By the end of 2027, expect at least one Indian pharma company to sign an AI discovery deal with a disclosed value. That number will matter more than any grant.
By Saraswati Chaubey, Writer
Have a tip? Write to us at editorial@startupfeed.in.
Liked this story? Follow StartupFeed on Google so our reporting reaches you first.
